# US 2013/0156796 A1 · Method of Treatment of Tumors That Are Resistant to EGFR Therapies by EGFR Antibody Cytotoxic Agent Conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156796 A1
- Document ID: US20130156796A1
- Status: Published application
- Kind: A1
- Application number: 13/682,948
- Filed: 2012-11-21
- Published: 2013-06-20
- Earliest claimed: 2011-11-21
- Assignees: ImmunoGen, Inc.
- Inventors: Julianto SETIADY; Peter U. Park; Thomas Chittenden
- Web page: https://patentgrep.com/patent/US20130156796A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting the growth of tumor cells that have developed EGFR and/or ALK resistance mechanisms. Methods of administering the EGFR antibody immunoconjugates to patients having resistant tumor cells is also disclosed.

## Claims

### Claim 1

A method of inhibiting the growth of epidermal growth factor receptor (EGFR)-expressing tumor cells that are resistant or refractory to EGFR therapy, said method comprising contacting said tumor cells with an effective amount of an EGFR antibody immunoconjugate.

### Claim 2 (depends on 1)

The method of claim 1, wherein said therapy comprised administration of an EGFR antibody or an EGFR kinase inhibitor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the EGFR therapy to which the cells are resistant is selected from the group consisting of: erlotinib, gefitinib, lapatinib, BIB2992, cetuximab, panitumumab, zalutumumab, necitumumab, and nimotuzumab.

### Claim 4 (depends on 1)

The method of claim 1, wherein at least one of the tumor cells: (1) contains one or more mutations in an EGFR-encoding gene; (2) contains one or more mutations in a PIK3CA, RAS, or PTEN encoding gene; (3) has an activated MET or IGF1R pathway; (4) has mesenchymal histology or has undergone epithelial-mesenchymal transition; or (5) has ERBB2 gene amplification or increased production of HER2 protein.

### Claim 5 (depends on 4)

The method of claim 4, wherein the mutated EGFR gene comprises a EGFRvIII or T790M mutation.

### Claim 6 (depends on 4)

The method of claim 4, wherein said at least one tumor cell contains one or more mutations in a PIK3CA, RAS, or PTEN encoding genes.

### Claim 7 (depends on 4)

The method of claim 4, wherein the MET or IGF1R pathway is activated.

### Claim 8

A method of treating cancer in a patient comprising administering an effective amount of an EGFR antibody immunoconjugate to inhibit growth of the tumor cells in said patient, wherein at least one of the tumor cells: (1) contains one or more mutations in an EGFR-encoding gene; (2) contains one or more mutations in a PIK3CA, RAS, or PTEN encoding gene; (3) has an activated MET or IGF1R pathway; (4) has mesenchymal histology or has undergone epithelial-mesenchymal transition; or (5) has ERBB2 gene amplification or increased production of HER2 protein.

### Claim 9

A method of treating cancer in a patient comprising:
(a) identifying tumor cells from said patient that (1) contain one or more mutations in an EGFR-encoding gene; (2) contain one or more mutations in a PIK3CA, RAS, or PTEN encoding gene; (3) have an activated MET or IGF1R pathway; or (4) have mesenchymal histology or have undergone epithelial-mesenchymal transition; and
(b) administering an effective amount of an EGFR antibody immunoconjugate to said patient.

### Claim 10 (depends on 8)

The method of claim 8, wherein said cancer is a squamous cell cancer, lung cancer, head and neck cancer, or an EGFR-positive cancer.

### Claim 11 (depends on 8)

The method of claim 8, wherein said MET activation is caused by MET gene amplification.

### Claim 12 (depends on 8)

The method of claim 8, wherein said patient previously failed or is currently failing an EGFR therapy.

### Claim 13 (depends on 12)

The method of claim 12, wherein said therapy comprised administration of an EGFR antibody or an EGFR kinase inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein said EGFR antibody is cetuximab or panitumumab.

### Claim 15 (depends on 13)

The method of claim 13, wherein said EGFR kinase inhibitor is erlotinib or gefitinib.

### Claim 16

A method of treating cancer in a patient comprising administering an effective amount of an EGFR antibody immunoconjugate to inhibit growth of the tumor cells in said patient, wherein at least one of the tumor cells is resistant to therapy comprising an anaplastic lymphoma kinase (ALK) inhibitor.

### Claim 17

A method of treating cancer in a patient comprising:
(a) identifying tumor cells from said patient that are resistant to at least one ALK inhibitor; and
(b) administering an effective amount of an EGFR antibody immunoconjugate to said patient.

### Claim 18 (depends on 16)

The method of claim 16, wherein at least one of the tumor cells contains an EML4-ALK translocation.

### Claim 19 (depends on 16)

The method of claim 16, wherein the cancer is non-small cell lung cancer.

### Claim 20 (depends on 16)

The method of claim 16, wherein the ALK inhibitor is crizotinib.

### Claim 21 (depends on 1)

The method of claim 1, wherein said immunoconjugate has the formula (A)-(L)-(C), wherein:
(A) is an antibody or antigen binding fragment thereof that specifically binds EGFR;
(L) is a linker; and
(C) is a cytotoxic agent; and
wherein said linker (L) links (A) to (C).

### Claim 22 (depends on 21)

The method of claim 21, wherein said EGFR antibody comprises the heavy chain variable region of SEQ ID NO: 1 and the light chain variable region of SEQ ID NOs: 2 or 3.

### Claim 23 (depends on 22)

The method of claim 22, wherein said linker is selected from the group consisting of a cleavable linker, a non-cleavable linker, a hydrophilic linker, and a dicarboxylic acid based linker.

### Claim 24 (depends on 23)

The method of claim 23, wherein said linker is a non-cleavable linker.

### Claim 25 (depends on 21)

The method of claim 21, wherein said linker is selected from the group consisting: N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP); N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) or N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB); N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC); N-sulfosuccinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (sulfoSMCC); N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB); N-succinimidyl-[(N-maleimidopropionamido)-tetraethyleneglycol]ester (NHS-PEG4-maleimide); N-(beta-maleimidopropyloxy)succinimide ester (BMPS); and gamma-maleimidobutyric acid N-succinimidyl ester (GMBS).

### Claim 26 (depends on 21)

The method of claim 21, wherein said cytotoxic agent is selected from the group consisting of a maytansinoid, maytansinoid analog, doxorubicin, a modified doxorubicin, benzodiazepine, taxoid, CC-1065, CC-1065 analog, duocarmycin, duocarmycin analog, calicheamicin, dolastatin, dolastatin analog, auristatin, tomaymycin derivative, and leptomycin derivative or a prodrug of the agent.

### Claim 27 (depends on 26)

The method of claim 26, wherein said cytotoxic agent is a maytansinoid.

### Claim 28 (depends on 27)

The method of claim 27, wherein said cytotoxic agent is N(2′)-deacetyl-N(2′)-(3-mercapto-1-oxopropyl)-maytansine (DM1) or N(2)-deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4).

### Claim 29 (depends on 1)

The method of claim 1, wherein the EGFR antibody immunoconjugate comprises an antibody which comprises the heavy chain variable region of SEQ ID NO: 1 and the light chain variable region of SEQ ID NOs: 2 or 3; the linker SMCC; and the maytansinoid DM1.

### Claim 30 (depends on 1)

The method of claim 1, wherein the EGFR antibody immunoconjugate is administered with an anti-neoplastic agent.

### Claim 31 (depends on 30)

The method of claim 30, wherein the EGFR antibody immunoconjugate is administered simultaneously with the anti-neoplastic agent.

### Claim 32 (depends on 30)

The method of claim 30, wherein the EGFR antibody immunoconjugate and anti-neoplastic agent are administered in any temporal order.

### Claim 33 (depends on 8)

The method of claim 8, wherein said patient is a human.
